Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018
Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018
SUMMARY
Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins.
The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.
Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 27 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 3 and 11 respectively.
Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Glioblastoma Multiforme (GBM), Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer and Vulvar Cancer.
The latest report Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins.
The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.
Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 27 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 3 and 11 respectively.
Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Glioblastoma Multiforme (GBM), Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer and Vulvar Cancer.
The latest report Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2018, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
- The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
- The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Human Papillomavirus Protein E6 (E6) - Overview
Human Papillomavirus Protein E6 (E6) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development
Abion Inc
BioNTech AG
Cancer Research Technology Ltd
Etubics Corp
Genexine Inc
Hookipa Biotech AG
Inovio Pharmaceuticals Inc
MedImmune LLC
Rottapharm Biotech Srl
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
Human Papillomavirus Protein E6 (E6) - Drug Profiles
ABN-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVAC-C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotype 16] vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 16] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-3106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-0457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TA-CIN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tricurin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for HPV Associated Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Papillomavirus Protein E6 (E6) - Dormant Products
Human Papillomavirus Protein E6 (E6) - Discontinued Products
Human Papillomavirus Protein E6 (E6) - Product Development Milestones
Featured News & Press Releases
Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase
Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112
Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference
Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech
Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
Oct 17, 2016: Hookipa Secures EUR 4.16 Million Additional Grant Support from the Austrian Research Promotion Agency (FFG) to Develop Arenavirus Vector-Based Cancer Immunotherapies
Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Human Papillomavirus Protein E6 (E6) - Overview
Human Papillomavirus Protein E6 (E6) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development
Abion Inc
BioNTech AG
Cancer Research Technology Ltd
Etubics Corp
Genexine Inc
Hookipa Biotech AG
Inovio Pharmaceuticals Inc
MedImmune LLC
Rottapharm Biotech Srl
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
Human Papillomavirus Protein E6 (E6) - Drug Profiles
ABN-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVAC-C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-188E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotype 16] vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 16] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-3106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-0457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TA-CIN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tricurin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for HPV Associated Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vvax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Papillomavirus Protein E6 (E6) - Dormant Products
Human Papillomavirus Protein E6 (E6) - Discontinued Products
Human Papillomavirus Protein E6 (E6) - Product Development Milestones
Featured News & Press Releases
Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase
Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112
Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference
Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech
Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
Oct 17, 2016: Hookipa Secures EUR 4.16 Million Additional Grant Support from the Austrian Research Promotion Agency (FFG) to Develop Arenavirus Vector-Based Cancer Immunotherapies
Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Abion Inc, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Cancer Research Technology Ltd, H1 2018
Pipeline by Etubics Corp, H1 2018
Pipeline by Genexine Inc, H1 2018
Pipeline by Hookipa Biotech AG, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by MedImmune LLC, H1 2018
Pipeline by Rottapharm Biotech Srl, H1 2018
Pipeline by Selecta Biosciences Inc, H1 2018
Pipeline by Touchlight Genetics Ltd, H1 2018
Pipeline by Transgene SA, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Abion Inc, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Cancer Research Technology Ltd, H1 2018
Pipeline by Etubics Corp, H1 2018
Pipeline by Genexine Inc, H1 2018
Pipeline by Hookipa Biotech AG, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by MedImmune LLC, H1 2018
Pipeline by Rottapharm Biotech Srl, H1 2018
Pipeline by Selecta Biosciences Inc, H1 2018
Pipeline by Touchlight Genetics Ltd, H1 2018
Pipeline by Transgene SA, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
Abion Inc
BioNTech AG
Cancer Research Technology Ltd
Etubics Corp
Genexine Inc
Hookipa Biotech AG
Inovio Pharmaceuticals Inc
MedImmune LLC
Rottapharm Biotech Srl
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
COMPANIES MENTIONED
Abion Inc
BioNTech AG
Cancer Research Technology Ltd
Etubics Corp
Genexine Inc
Hookipa Biotech AG
Inovio Pharmaceuticals Inc
MedImmune LLC
Rottapharm Biotech Srl
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
